Allarity Therapeutics Inc (ALLR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Allarity Therapeutics Inc (ALLR) has a cash flow conversion efficiency ratio of -0.330x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.24 Million) by net assets ($9.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Allarity Therapeutics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Allarity Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Allarity Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Allarity Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Allarity Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wescoal Holdings Ltd
JSE:SLG
|
-0.815x |
|
Paru Co. Ltd
KQ:043200
|
-0.010x |
|
Oncoinvent ASA
OL:ONCIN
|
-0.505x |
|
Only World Group Holdings Bhd
KLSE:5260
|
0.074x |
|
Sala @ Sathorn Property Fund
BK:SSPF
|
0.003x |
|
Central Motek Co Ltd
KO:308170
|
-0.028x |
|
Eagon Ind
KO:008250
|
0.033x |
|
Mene Inc
V:MENE
|
0.048x |
Annual Cash Flow Conversion Efficiency for Allarity Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Allarity Therapeutics Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see ALLR company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.83 Million | $-14.82 Million | -1.508x | -2.64% |
| 2024-12-31 | $11.81 Million | $-17.35 Million | -1.469x | -131.71% |
| 2023-12-31 | $-2.75 Million | $-12.74 Million | 4.633x | +152.07% |
| 2022-12-31 | $1.89 Million | $-16.82 Million | -8.898x | -1010.55% |
| 2021-12-31 | $18.78 Million | $-15.05 Million | -0.801x | -196.70% |
| 2020-12-31 | $26.85 Million | $-7.25 Million | -0.270x | +44.18% |
| 2019-12-31 | $20.90 Million | $-10.11 Million | -0.484x | -218.50% |
| 2018-12-31 | $27.90 Million | $-4.24 Million | -0.152x | +95.55% |
| 2017-12-31 | $394.04K | $-1.34 Million | -3.413x | -346.16% |
| 2016-12-31 | $5.20 Million | $-3.98 Million | -0.765x | -85.86% |
| 2015-12-31 | $4.93 Million | $-2.03 Million | -0.412x | -- |
About Allarity Therapeutics Inc
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead d… Read more